Genetic Analysis: Record sales, narrowed losses, and global expansion marked a strong year in microbiome diagnostics

About this update from Genetic Analysis As

Record sales and improved financials in 2025 were driven by new product launches, U.S. and China expansion, and strategic partnerships. Net loss narrowed, cash flow turned positive, and the company strengthened its position in the rapidly growing microbiome diagnostics market.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Genetic Analysis As